Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772495 | 0.97 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1771539 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1772166 | 0.88 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1771177 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1773103 | 0.86 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1771201 | 0.86 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL2213984 | 0.84 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1771130 | 0.84 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1120179 | 0.83 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL1771818 | 0.83 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | PIK3CD 111/4885PIK3CA 64/4885PIK3CG 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.